disease) from 13 centers in 5 countries (Argentina, Brazil, Chile, Mexico, and Peru). Mean age was 54.3±14.3 years old, 58.8% were female, and 60.2% had a liver biopsy. Around 18% had significant fibrosis, 18.7% advanced fibrosis, and 16.2% had cirrhosis. Additionally, 21.8% were homozygous carriers of the rs738409 risk polymorphism (*PNPLA3* I148M variant), 42.5% were heterozygotes, and 35.7% were non-carriers. In an adjusted multivariable model, only age (odds ratio [OR]:1.03; 95%CI:1.01−1.04; p=0.030), body mass index (BMI) (OR:1.04; 95%CI:1.01−1.08, p=0.008), prediabetes/diabetes (OR:2.41; 95%CI:1.48−3.91, p<0.0001), and *PNPLA3* risk allele carriers (heterozygotes: OR:2.86, 95%CI:1.78−4.61; p<0.0001, and homozygous: OR:25.37, 95%CI:4.30−149.54; p<0.001) were associated with a higher risk of advanced fibrosis. Similar results were observed in multivariable models to assess the risk of cirrhosis. Prevalence of advanced fibrosis or cirrhosis was higher in those with prediabetes/diabetes and homozygous carriers of the *PNPLA3* I148M variant than those without both risk factors (48.6% vs. 27.9%, p<0.0001) (Figure).

Conclusions: Age, BMI, prediabetes, diabetes, and carriers of the *PNPLA3* risk allele carriers were the leading risk factors for advanced fibrosis in SLD. *PNPLA3* I148M variant carriers are frequent in SLD patients in Latin America, and genotyping could be established to stratify the risk of liver fibrosis routinely in clinical practice. (Supported Fondecyt #1241450)



Figure

https://doi.org/10.1016/j.aohep.2024.101597

O3- RECOMPENSATION IN PATIENTS WITH CIRRHOSIS PRIOR TO FIRST LINE SYSTEMIC THERAPY IS ASSOCIATED WITH SIMILAR SURVIVAL OUTCOMES COMPARED TO COMPENSATED CIRRHOSIS

FEDERICO PIÑERO[1], Margarita Anders[2], Carla Bermúdez[3], Diego Arufe[4], Adriana Varón[5], Ana Palazzo[6], Jorge Rodriguez[7], Oscar Beltrán[5], Daniela Simian[8], Leonardo Gomes da Fonseca[9], Ezequiel Ridruejo[10], Norberto Tamagnone[11], Hugo Cheinquer[12], Diana Bejarano[13], Juan Ignacio Marín[14], Federico Orozco Ganem[2], Josefina Pagés[1], Jaime Poniachik[8], Sebastián Marciano[3], Virginia Reggiardo[11], Manuel Mendizabal[1]

[1] *HOSPITAL UNIVERSITARIO AUSTRAL, Pilar, Argentina*
[2] *Hospital Alemán, Buenos Aires, Argentina*
[3] *Hospital Italiano de Buenos Aires, Buenos Aires, Argentina*
[4] *Sanatorio Sagrado Corazón, Buenos Aires, Argentina*
[5] *Fundación Cardioinfantil, Bogotá, Colombia*
[6] *Hospital Padilla, Tucumán, Argentina*
[7] *Hospital Central, Mendoza, Argentina*
[8] *Hospital Clínico de la Universidad de Chile, Santiago, Chile*
[9] *Instituto do Cancer do Estado de São Paulo, Hospital das Clínicas, Universidade São Paulo, Sao Paulo, Brasil*
[10] *Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Buenos Aires, Argentina*
[11] *Hospital Centenario, Rosario, Argentina*
[12] *Hospital das Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brasil*
[13] *Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia*
[14] *Hospital Pablo Tobón Uribe, Medellín, Colombia*

Conflict of interest: No

Introduction and Objectives: The term *"recompensation"* of cirrhosis was proposed in the latest BAVENO VII, underlying dynamic events and prognosis in cirrhosis. However, there is uncertainty regarding its prognosis in patients with advanced hepatocellular carcinoma (HCC) treated with first line systemic therapies (1L). We aimed to compare post-1L survival between compensated (CC), decompensated (DC), and recompensated (RC) cirrhosis.

Patients / Materials and Methods: A multicenter prospective Latin-American cohort study including advanced HCC patients with cirrhosis who received any 1L was conducted from 2018 to 2024. Three groups were defined: CC (had never presented decompensation); DC (presenting any decompensated event associated with portal hypertension at time of 1L), and RC group (prior history of any decompensation event at HCC diagnosis who were compensated at time of 1L). Survival since date of 1L was compared using Cox proportional hazard analysis.

Results and Discussion: Overall, 306 patients received 1L, including sorafenib 60.5%, atezolizumab + bevacizumab 29.7%, lenvatinib 9.1%, and nivo/pembrolizumab 0.6%. Of these, 83.3% presented cirrhosis. Median 1L treatment duration was 5.1 months with a median overall survival since 1L of 16.0 months (range 12.9-18.3). Significant differences were observed between CC (n=167), DC (n=31) and RC (n=42) groups (Table). In the RC group, median time from decompensation to recompensation was 12.0 months (range 1.9-25.9); being ascites the most frequent event (78.6%). DC group presented decreased post-1L survival [median 8.6 months vs 17.2 months in CC [adjusted HR 1.9 (95% CI 1.05-3.5); P=0.03], while no significant survival difference was observed between RC and CC [median survival 12.5 months; aHR 1.3 (95% CI 0.81-2.1); P=0.28] (Figure). Lower access to second line therapy was observed in DC group.

Conclusions: Patients with cirrhosis and advanced HCC who achieve recompensation may benefit from systemic therapies. This demands an observation period of follow up before precluding 1L in decompensated cirrhosis.

VARIABLE	*Compensated n=167 (69.6%)*	*Recompensated n=42 (17.5%)*	*Decompensated n=31 (12.9%)*	*P values*
Age, years (± SD)	66 ± 8.2	66 ± 9.4	64 ± 10	0.54
Gender, Male, n (%)	134 (80.2)	30 (71.4)	22 (71.0)	0.26
Obesity, n (%)	39 (26.9)	7 (17.5)	5 (17.9)	0.39
Comorbidities, n (%)	94 (56.3)	30 (71.4)	17 (54.8)	0.18
Etiology of liver disease, n (%)				
Viral/non-viral	76 (45.5)/91 (54.5)	12 (28.6)/30 (71.4)	8 (25.8)/23 (74.2)	0.03
Hepatitis C	67 (40.1)	12 (28.6)	6 (19.3)	0.05
MASLD	45 (26.9)	18 (42.9)	9 (29.0)	0.13
Alcoholic liver disease	20 (12.0)	4 (9.5)	6 (19.3)	0.08
Pre-1L treatment characteristics				
Child Pugh A/B, n (%)	143 (85.6)/24 (14.4)	38 (92.7)/3 (7.3)	6 (20.0)/24 (80.0)	<.0001
Mild Ascites, n (%)	-	-	28 (90.3)	<.0001
HE grades I-II, n (%)	-	-	7 (22.6)	<.0001
ECOG 0-1, n (%)	163 (97.6)	38 (92.7)	20 (64.5)	<.0001
Median total Bilirubin, mg/dl (IQR)	1.0 (0.8-1.55)	1.0 (1.0-1.3)	1.6 (1.0-2.2)	0.003
Median Albumin, g/dl (IQR)	3.6 (3.5-4.0)	3.6 (3.5-3.6)	3.3 (3.0-3.6)	<.0001
Median INR, (IQR)	1.0 (1.0-1.2)	1.0 (1.0-1.1)	1.2 (1.1-1.4)	<.0001
Median serum AFP, ng/ml (IQR)	134.0 (11.7-1235)	607.0 (29-5843)	227.5 (16.4-1585)	0.34
AFP ≥400 ng/ml, n (%)	46 (27.5)	10 (24.4)	10 (32.3)	0.77
Macrovascular tumor invasion, n (%)	60 (35.9)	4 (9.8)	11 (35.5)	0.002
Metastatic disease, n (%)	60 (35.9)	12 (29.3)	12 (38.7)	0.67
BCLC, n (%)				
A	2 (1.2)	1 (3.3)	-	0.044
B	45 (27.9)	13 (43.3)	62 (12.9)	
C	114 (70.8)	16 (53.3)	27 (87.1)	

Abbreviations: HCC: hepatocellular carcinoma, AFP: alpha-fetoprotein; IQR: interquartile range. HE: hepatic encephalopathy.

Comparison between patients with cirrhosis presenting compensated, recompensated and descompensated cirrhosis



https://doi.org/10.1016/j.aohep.2024.101598

OP-1 LONG-TERM EFFICACY AND SAFETY OF OPEN-LABEL SELADELPAR TREATMENT IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS: INTERIM 2-YEAR RESULTS FROM THE ASSURE STUDY

Palak J. Trivedi[1], Cynthia Levy[2], Kris V. Kowdley[3], Stuart C. Gordon[4], Christopher L. Bowlus[5], Maria Carlota Londoño Hurtado[6], Gideon M. Hirschfield[7], Aliya F. Gulamhusien[3], Eric J. Lawitz[8], Alejandra Villamil[9], Alma Ladron de Guevara Cetina[10], Marlyn J. Mayo[11], Ziad H. Younes[12], Oren Shibolet[13], Kidist K. Yimam[14], Daniel S. Pratt[15], Jeong Heo[16], Ulrike Morgera[17], Pietro Andreone[18], Andreas E. Kremer[19], Christophe Corpechot[20], Aparna Goel[21], Adam Peyton[22], Hany Elbeshbeshy[23], Daria B. Crittenden[24], Carrie Heusner[24], Sarah Proehl[24], Shuqiong Zhou[24], Charles A. McWherter[24]

[1] *University of Birmingham, Birmingham, Reino Unido (RU)*
[2] *University of Miami, Miami, Estados Unidos (EEUU)*
[3] *Liver Institute Northwest, Seattle, Estados Unidos (EEUU)*
[4] *Division of Gastroenterology and Hepatology, Henry Ford Health, Detroit, Estados Unidos (EEUU)*
[5] *Department of Medicine, Division of Gastroenterology and Hepatology, University of California Davis Health, Sacramento, Estados Unidos (EEUU)*
[6] *The Liver Unit, Hospital Clínic Barcelona, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer, CIBEREHD, European Reference Network on Hepatological Diseases, Barcelona, España*
[7] *Division of Gastroenterology and Hepatology, Toronto Centre for Liver Disease, University of Toronto, Toronto, Canadá*
[8] *The Texas Liver Institute, University of Texas Health, San Antonio, Estados Unidos (EEUU)*
[9] *Hepatic Autoimmunity Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina*
[10] *Centro de Investigación y Gastroenterología, Mexico City, México*
[11] *Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern, Dallas, Estados Unidos (EEUU)*
[12] *GastroOne, Germantown, Estados Unidos (EEUU)*
[13] *The Research Center for Digestive Tract and Liver Diseases, Tel Aviv Sourasky Medical Center and Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel*
[14] *Department of Hepatology and Liver Transplantation, California Pacific Medical Center, San Francisco, Estados Unidos (EEUU)*
[15] *Massachusetts General Hospital, Harvard Medical School, Boston, Estados Unidos (EEUU)*
[16] *Department of Internal Medicine, Pusan National University and Biomedical Research Institute, Busan, Corea (del Sur)*
[17] *Outpatient Clinic, Charité, Universitätsmedizin Berlin, Berlin, Alemania*
[18] *University of Modena and Reggio Emilia, Internal Medicine, Baggiovara Hospital, Modena, Italia*
[19] *University Hospital Zurich, Zurich, Suiza*
[20] *Reference Centre for Inflammatory Biliary Diseases and Auto-Immune Hepatitis, Saint-Antoine Hospital, Paris, Francia*
[21] *Department of Medicine, Stanford University, Palo Alto, Estados Unidos (EEUU)*
[22] *Miami Veterans Affairs Healthcare System, Miami, Estados Unidos (EEUU)*
[23] *Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, Estados Unidos (EEUU)*
[24] *CymaBay, a Gilead Sciences Company, Fremont, Estados Unidos (EEUU)*

Conflict of interest: Yes, Full disclosures sent separately.

Introduction and Objectives: Seladelpar reduces biochemical markers of cholestasis and pruritus in patients with primary biliary cholangitis. ASSURE (NCT03301506) is an ongoing, open-label, long-term Phase 3 trial of seladelpar in patients rolling over from Phase 3